赛伦生物(688163) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥25,621,279.55, a decrease of 2.59% compared to ¥26,301,356.47 in the same period last year[4] - Net profit attributable to shareholders increased by 154.77% to ¥3,757,316.22 from ¥1,474,787.04 year-on-year[4] - Basic and diluted earnings per share rose by 200.00% to ¥0.03 from ¥0.01 in the previous year[4] - Total operating revenue for Q1 2025 was ¥25,621,279.55, a decrease of 2.58% from ¥26,301,356.47 in Q1 2024[18] - Net profit for Q1 2025 was ¥3,757,316.22, significantly up from ¥1,474,787.04 in Q1 2024, marking an increase of 154.5%[19] - Basic and diluted earnings per share for Q1 2025 were both ¥0.03, compared to ¥0.01 in Q1 2024[19] - Total comprehensive income for Q1 2025 was ¥3,757,316.22, compared to ¥1,474,787.04 in Q1 2024, reflecting a strong performance[19] Research and Development - Total R&D investment was ¥3,182,878.72, down 48.68% from ¥6,202,207.19 in the same period last year, with R&D expenses accounting for 12.42% of operating revenue, a decrease of 11.16 percentage points[5] - Research and development expenses decreased to ¥3,182,878.72 in Q1 2025 from ¥6,202,207.19 in Q1 2024, a reduction of 48.7%[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥20,933,375.96, slightly improved from -¥21,796,451.38 in the previous year[4] - Cash flow from operating activities for Q1 2025 was negative at -¥20,933,375.96, slightly improved from -¥21,796,451.38 in Q1 2024[22] - Cash flow from investing activities generated a net inflow of ¥189,750,738.98 in Q1 2025, compared to a net outflow of -¥5,046,128.03 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was ¥350,924,252.18, up from ¥124,093,875.96 in Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,116,016,974.45, a decrease of 0.36% from ¥1,120,033,956.92 at the end of the previous year[5] - The company's total liabilities decreased to ¥17,122,128.87 from ¥24,533,348.17, a reduction of 30.3%[15] - The total assets as of March 31, 2025, were ¥1,116,016,974.45, down from ¥1,120,033,956.92, a decrease of 0.4%[14] - The company's equity attributable to shareholders increased to ¥1,098,894,845.58 from ¥1,095,500,608.75, a rise of 0.2%[15] - The total current assets decreased slightly to ¥912,262,557.85 from ¥916,362,945.70, a decline of 0.4%[13] - Accounts receivable increased to ¥49,203,485.97 from ¥36,678,957.69, reflecting a growth of 34.0%[13] - The inventory level rose to ¥47,473,661.57 from ¥43,275,462.94, an increase of 9.1%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,061[8] - Major shareholders include Zhao Aixian with 34.05% and Shanghai Zhiyuan Investment Co., Ltd. with 22.18% of shares[9] - The company has not reported any significant changes in its major shareholders or their shareholdings during the reporting period[10] Other Information - The company reported non-recurring gains of ¥3,825,059.39, primarily from bank wealth management income and government subsidies[7] - There are no new strategies or major product developments mentioned in the current report[11] - The company reported a significant increase in investment income, rising to ¥2,266,175.69 in Q1 2025 from ¥645,457.55 in Q1 2024[18] - The company reported a significant decrease in short-term borrowings, reflecting improved liquidity management[15]